In the company’s news yesterday,
Alpharma Inc. published its third quarter results and those results show the company has advanced towards meeting its goal announced earlier this year of producing positive earnings for the last half of 2008.
Increases in livestock sales and the resulting need for additional products boosting animal health in the United States helped push Alpharma into the black. Both revenue and operating income increased, leading to higher earnings per share. Alpharma recorded revenue of $175.7 million, a 32% increase in revenue from the third quarter of 2007. Operating income reached $9.7 million after subtracting costs from King Pharmaceuticals, Inc.’s unsolicited takeover bid for all of Alpharma’s common stock. Excluding the extraordinary costs for the takeover bid, operating income was $13.9 million. Earnings per share were $0.10, or $0.16 when the takeover costs are excluded.
According to Dean Mitchell, President and Chief Executive Officer, Alpharma’s results are “in line with our guidance to deliver positive earnings in the second half of 2008. While significant investments during the first half of this year were necessary to expand our commercial infrastructure and to support the launch of the FLECTOR® Patch, our third quarter results demonstrate initial returns on those investments. In addition to its successful launch, prescription growth of FLECTOR® Patch has continued as a result of enhanced formulary coverage and ongoing promotional activities. Performance in our Animal Health business has strengthened in the third quarter as demand for our U.S. livestock products has improved, reflecting some easing of input cost pressures on our customers.”
He continued, “We also recently announced that the new drug application for EMBEDA™ Capsules has been accepted for priority review by the U.S. Food and Drug Administration, and will be reviewed at a joint meeting of the Anesthetic and Life Support Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee on November 14, 2008.”
The company is continuing with its repurchase of shares as authorized by the Board of Directors last April. In the third quarter, Alpharma spent $35.5 million and bought back 1.5 million shares of common stock. In light of the company’s third quarter results, it has revised its forecast for diluted earnings per share on a yearly basis to a range of $0.25 to $0.35.
About QualityStocks
QualityStocks, based in Scottsdale, Arizona is a free service that collects data from hundreds Small-Cap and Micro-Cap online Investment Newsletters into one Free Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their advertising efforts and now has over 500,000+ subscribers that receive The Daily Stock Newsletters.
To sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net
Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
